Investing in transformative biotech companies
Humanity will always depend on medicines. Continuous innovation in the biotech sector is a given. Bringing better medicines to the market all the time. Aescap is able to select those companies that are developing tomorrow’s medicines. Thereby it can achieve excellent returns over the medium term, without taking large risks.
The Aescap funds invest in highly innovative publicly traded biotech/life sciences companies. The funds are supervised by an AIFM and managed by an experienced investment team with an excellent track record. The members of the investment team significally invest in the funds themselves. Aescap is heavily involved with the companies it invests in, acting as a private equity investor on the stock market. The name Aescap is derived from ‘Aesculapius’, the Roman god of Medicine, and ‘Capital’.
The companies in the portfolios of the Aescap biotech funds address medical needs that are not met by products available today. We believe everybody has the right to receive the best medical care available. Aescap’s investments have positively affected society and have already resulted in an improvement of the quality of life of millions of people worldwide.
Both Aescap Funds are classified as article 8 fund, according to the Sustainable Finance Disclosure Regulation (SFDR).
Update via webcast
We regularly organise information meetings for existing and potential investors. In these meetings we share our investment philosophy as well as methodology. The next meeting takes place on June 29th.
Meet the investment team
The Aescap investment team, led by portfolio manager Patrick Krol, consists of experienced professionals with different backgrounds in the health care industry. We aim to provide a good financial return to our investors, and in parallel contribute to improving the well-being of millions of people. Our team members invest in the Aescap funds themselves with over 25 million euro.
The biotech sector, also known as the life sciences sector, is a large and fast-growing sector, driven by an aging population and a high pace of innovation. New medicines like RNA, gene and cell therapies will replace the vast majority of medicine over the coming decades. With around 1000 public biotech companies in the EU and US, it requires sector specific expertise to find de-risked companies with a high earning power that are still undervalued.
Subscribe to our newsletter here.
Find out more about Aescap in this animation.
- Next-generation medicine
- Outstanding management
- High-growth companies
- Diversification within our focus
- Undervalued companies
- Buy and Sell discipline
UCB: An interesting biopharmaceutical growth story
UCB is a biopharma company with over 8 600 employees, headquartered in Brussels, Belgium The company develops and manufactures multiple medicines, sold in 40 countries. In this company showcase we describe why we think UCB is an interesting biopharmaceutical growth story, even after 95 years of existence.
Aescap’s portfolio company Albireo acquired for 84% premium + 44% via CVR
We are reporting to you from the JPMorgan conference in San Francisco where Ipsen and our portfolio company Albireo announced that Ipsen has made an offer to acquire Albireo
Zai Lab’s share price is up 40% after positive phase 3 results in lung cancer
Portfolio company Zai Lab and its partner Novocure announced that the phase 3 study investigating their new therapy for late-stage lung cancer patients resulted in improved overall survival